Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own0.40% Shs Outstand229.28M Perf Week-4.02%
Market Cap2.52B Forward P/E- EPS next Y-0.23 Insider Trans1.96% Shs Float204.86M Perf Month19.61%
Income-189.60M PEG- EPS next Q-0.16 Inst Own83.60% Short Float16.74% Perf Quarter69.18%
Sales71.50M P/S35.21 EPS this Y41.30% Inst Trans6.11% Short Ratio5.48 Perf Half Y186.68%
Book/sh-0.81 P/B- EPS next Y67.60% ROA-45.50% Target Price10.67 Perf Year81.49%
Cash/sh1.43 P/C7.67 EPS next 5Y- ROE145.60% 52W Range3.55 - 11.74 Perf YTD94.68%
Dividend- P/FCF43.41 EPS past 5Y0.90% ROI-43.80% 52W High-6.52% Beta2.15
Dividend %- Quick Ratio1.80 Sales past 5Y-27.50% Gross Margin93.40% 52W Low209.15% ATR0.44
Employees115 Current Ratio1.80 Sales Q/Q353.70% Oper. Margin- RSI (14)62.20 Volatility4.53% 4.64%
OptionableYes Debt/Eq- EPS Q/Q27.00% Profit Margin- Rel Volume0.38 Prev Close10.98
ShortableYes LT Debt/Eq- EarningsAug 03 AMC Payout- Avg Volume6.26M Price10.98
Recom1.60 SMA202.13% SMA5018.75% SMA20082.72% Volume1,908,710 Change-0.05%
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Jun-17-09Initiated Boenning & Scattergood Neutral
Dec-15-08Reiterated Lazard Capital Buy $7 → $8
Nov-24-08Reiterated Lazard Capital Buy $7
Oct-16-08Initiated Merriman Curhan Ford Buy
Aug-14-08Initiated Banc of America Sec Neutral $7
Aug-26-16 09:00AM  Why Exelixis (EXEL) Could Be Positioned for a Surge
Aug-25-16 09:38AM  4 stocks to watch at MarketWatch
Aug-24-16 12:39PM  Mobileye And Three More Stocks Breaking Out at Forbes -6.37%
08:30AM  Exelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019 Business Wire
Aug-23-16 12:07PM  4 Biotech Stock Charts You Must See
Aug-22-16 11:25AM  ETFs with exposure to Exelixis, Inc. : August 22, 2016
08:35AM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Aug-11-16 01:04PM  EXELIXIS, INC. Financials
12:45PM  ETFs with exposure to Exelixis, Inc. : August 11, 2016
Aug-10-16 11:19AM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
Aug-09-16 05:26PM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities
Aug-04-16 03:52PM  Exelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues +17.89%
03:46PM  Why Exelixis (EXEL) Stock Is Soaring Today
11:16AM  Correction: Earns-Exelixis story
10:53AM  Don't Roll the Dice on Central Bank News
08:00AM  Earnings Wrap: Transocean (RIG), XPO Logistics (XPO), Exelixis (EXEL), 2 More at Insider Monkey
Aug-03-16 09:10PM  Edited Transcript of EXEL earnings conference call or presentation 3-Aug-16 9:00pm GMT
06:47PM  Exelixis reports 2Q loss
05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today
04:13PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:06PM  Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update Business Wire
07:07AM  Q2 2016 Exelixis Inc Earnings Release - After Market Close
Aug-02-16 10:30AM  Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
Aug-01-16 06:38PM  What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?
06:38PM  Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?
06:36PM  Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
11:55AM  Exelixis (EXEL) Q2 Earnings Preview: Stock Likely to Gain?
Jul-29-16 03:51PM  Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Jul-23-16 03:23PM  Cancer Stocks: 2 to Buy, 1 to Avoid at Motley Fool
Jul-22-16 10:25AM  Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy Business Wire
Jul-21-16 02:55PM  Exit of Biogen CEO George Scangos could be big for Bay Area biotechs at bizjournals.com
Jul-20-16 08:45AM  5 Stocks to Buy and Hold for the Next Decade at Motley Fool
Jul-12-16 04:19PM  Exelixis to Release Second Quarter 2016 Financial Results on Wednesday, August 3, 2016 Business Wire
Jul-11-16 09:23AM  Pfizer Reports Positive Data on Kidney Cancer Drug Sutent
Jul-10-16 07:21AM  Here's How Pfizer's Protecting Its Kidney Cancer Drug From New Competitors at Motley Fool
Jul-08-16 09:41AM  The Reason Why Exelixis Skyrocketed 20.5% in June at Motley Fool
06:58AM  Biotech Stock Mailbag: Heron, Exelixis
Jul-01-16 08:23AM  Merger and Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizers $5.2 Billion Purchase
Jun-30-16 09:09AM  Merger and Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizers $5.2 Billion Purchase
09:09AM  Merger and Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizers $5.2 Billion Purchase Company Spotlight
Jun-29-16 09:30AM  Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining and Lexington Realty Trust
Jun-28-16 03:27PM  Explosive Stocks Under $10
Jun-23-16 11:30AM  Biotech Stock Bounce Picks Up Momentum at Forbes
Jun-15-16 08:03AM  4 Cancer Drug Developers You Need to Have on Your Radar This Year at Motley Fool
06:00AM  'Mad Money' Lightning Round: I'm Sticking With Wells Fargo
Jun-08-16 03:45PM  Exelixis, Inc. Setting New Standard of Care at Motley Fool
09:02AM  Research Coverage Scans Stocks on the Biotechnology Industry for Today
Jun-07-16 03:46PM  Exelixis Up on Positive Kidney Cancer Data on Cabometyx
08:15AM  Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher
Jun-06-16 05:08PM  Why Transocean, Exelixis, and CF Industries Jumped Today at Motley Fool +11.23%
04:18PM  Exelixis, Inc. Gets Some ASCO Love at Motley Fool
11:21AM  Heres Why These Five Stocks Are Surging Today at Insider Monkey
09:23AM  Exelixis (EXEL) Stock Gains on Positive Trial Results for Kidney Cancer Treatment
07:47AM  Exelixis's stock surges after positive results from trial of kidney cancer treatment at MarketWatch
07:30AM  Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting Business Wire
Jun-05-16 07:30PM  Exelixis Inc Investor/Analyst Briefing to Review Cabozantinib Data at the American Society of Clinical Oncology Annual Meeting scheduled for 7:30 pm ET today
07:35AM  Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO Business Wire
07:30AM  Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting Business Wire
Jun-03-16 10:03AM  Exelixis, Inc. Rides Cabometyx's Coattails to Big Gains in May at Motley Fool
May-31-16 03:04PM  These 2 Billionaires Are Dumping Exelixis' Stock. Should You? at Motley Fool
May-27-16 03:31PM  This New Data Could Push Exelixis' Cabometyx Over $1 Billion in Peak Annual Sales at Motley Fool
May-26-16 04:14PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secu
May-24-16 05:15PM  Exelixis' Kidney Cancer Drug Cabometyx Positive in Phase II
May-23-16 09:02AM  Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Business Wire +7.91%
May-16-16 10:26AM  XBI and IHI Rose despite the Biotechnology Sectors Sluggish Week
08:45AM  Exelixis (EXEL) Worth a Look: Stock Up 8.1% in Session
May-12-16 04:50PM  Exelixis, Inc. Prepares for Blastoff at Motley Fool +6.13%
May-11-16 07:40PM  ETFs with exposure to Exelixis, Inc. : May 11, 2016
May-09-16 12:01PM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q1, 2016 By the Numbers
May-05-16 04:05PM  Exelixis to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10 Business Wire +8.31%
03:25PM  Exelixis (EXEL) Reports Wider-than-Expected Loss in Q1
07:35AM  3 Big Pharma Stocks With Credible Threats to Their Blockbusters at 24/7 Wall St.
01:19AM  Edited Transcript of EXEL earnings conference call or presentation 4-May-16 9:00pm GMT Thomson Reuters StreetEvents
May-04-16 05:13PM  Exelixis reports 1Q loss AP -7.28%
05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today CCBN
04:10PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
04:05PM  Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate Update Business Wire
12:01PM  2 Big Reasons Why Shares of Exelixis, Inc. Soared 15% in April at Motley Fool
07:07AM  Q1 2016 Exelixis Inc Earnings Release - After Market Close CCBN
May-03-16 09:50AM  Drug Stocks Reporting Mid-Week: MRK, ABC, ENDP & More Zacks
May-02-16 10:22AM  Exelixis (EXEL): What's Ahead for the Stock in Q1 Earnings? Zacks
Apr-27-16 03:48PM  Better Buy: Exelixis, Inc. vs. Roche at Motley Fool
Apr-26-16 04:05PM  Exelixis to Release First Quarter 2016 Financial Results on Wednesday, May 4, 2016 Business Wire
03:00PM  Exelixis, Inc.'s Cabometyx Approved: Let the Kidney Cancer Battle Begin! at Motley Fool
12:19PM  Pay Attention to These 5 Stocks Making Big Moves Today at Insider Monkey
Apr-25-16 04:15PM  Peninsula drug developer scores comeback win for cancer-fighting tablet at American City Business Journals +5.67%
04:04PM  ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy Business Wire
04:00PM  Exelixis, Inc. Conference Call to Discuss U.S. FDA Approval of CABOMETYX Tablets scheduled for 4:00 pm ET today CCBN
02:52PM  Exelixis Gets FDA Approval For Its CABOMETYX Tablets Benzinga
Apr-22-16 01:09PM  Why Are These Stocks Trading Deep in Red on Friday? at Insider Monkey
Apr-20-16 12:06PM  Exelixis-Discovered Compounds to Be Featured in 18 Presentations at 2016 ASCO Annual Meeting Business Wire
Apr-07-16 10:43AM  Ignore Exelixis, Inc.: Here Are 3 Better Stocks at Motley Fool
Apr-05-16 08:06AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : April 5, 2016
Apr-04-16 11:43AM  Exelixis (EXEL) Stock Climbs, Stifel Upgrades at TheStreet +5.19%
07:42AM  Exelixis upgraded by Stifel
Mar-22-16 09:00AM  Are These Biotech Stocks Worth your Attention? CELG, ARIA, EXEL, and CMRX Accesswire +5.96%
Mar-15-16 05:41PM  Exelixis, Inc.'s EKG-Like Stock Chart Hits a Low Spot at Motley Fool -10.43%
08:03AM  Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb at Motley Fool
Mar-09-16 10:30AM  Why Exelixis' Stock Dropped 10% on Tuesday at Motley Fool
Mar-07-16 03:02PM  Exelixis, Inc. Partnering Before Approval at Motley Fool +5.11%
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. The company has received regulatory approval for two separate formulations of cabozantinib for the treatment of certain forms of kidney and thyroid cancer and marketed as CABOMETYX tablets in the United States and COMETRIQ capsules in the United States and European Union respectively. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in the United States and European Union; and is being evaluated for further potential indications by Roche and Genentech under collaboration with Exelixis. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Option Exercise9.7342,338411,949174,354Aug 05 07:29 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Sale11.0042,338465,718132,016Aug 05 07:29 PM
Hessekiel JeffreyEVP and General CounselJun 01Option Exercise1.70200,000340,000230,367Jun 02 06:37 PM
WILLSEY LANCEDirectorMay 11Buy4.9520,00099,000568,273May 11 05:23 PM
WILLSEY LANCEDirectorMay 09Buy4.9740,000198,900548,273May 11 05:23 PM
WILLSEY LANCEDirectorDec 11Buy4.7850,000239,000494,975Dec 11 07:43 PM
WILLSEY LANCEDirectorDec 10Buy4.9950,000249,550444,975Dec 11 07:43 PM
Lamb PeterEVP, Discovery Research & CSOOct 16Option Exercise5.6351,549290,22188,022Oct 19 05:08 PM
Lamb PeterEVP, Discovery Research & CSOOct 16Sale5.8051,549298,98436,473Oct 19 05:08 PM
Lamb PeterEVP, Discovery Research & CSOOct 13Option Exercise5.636003,37837,073Oct 14 05:05 PM
Lamb PeterEVP, Discovery Research & CSOOct 13Sale5.806003,48036,473Oct 14 05:05 PM
Lamb PeterEVP, Discovery Research & CSOOct 12Option Exercise5.63300,2761,690,554336,749Oct 14 05:05 PM
Lamb PeterEVP, Discovery Research & CSOOct 12Sale5.84300,2761,753,31236,473Oct 14 05:05 PM